MC2 Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Horsholm Denmark (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2017
NCT03308799
First Marketed Drug
2020
betamethasone (celestone)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Drug Delivery Solutions Ltd. (part of MC2 Therapeutics) | MC2 | MC2 Therapeutics